

HOW TO OPTIMISE EFFICACY AND SAFETY OF TARGETED AGENT/IO MANAGEMENT STRATEGIES IN ADVANCED SOLID TUMOURS: SINGLE AGENTS, COMBINATIONS AND BIOMARKERS

Chairs

Jens Bedke, Tübingen, Germany

Tim Meyer, London, UK

SATURDAY, 18 SEPTEMBER 2021		
18:45 - 20:15 CEST, CHANNEL 5		
18:45	Live introduction	Jens Bedke Tübingen, Germany
18:50	Optimal selection of patients with untreated advanced renal carcinoma for combination and monotherapy regimens: Agents, combinations and emerging biomarkers	Jens Bedke Tübingen, Germany
19:05	Optimal selection of patients with untreated advanced hepatocellular cancer for combination and monotherapy regimens: Agents, combinations and emerging biomarkers	Masafumi Ikeda Kashiwa, Japan
19:20	Optimal selection of patients with platinum-pretreated advanced endometrial carcinoma for combination and monotherapy regimens: Agents, combinations and emerging biomarkers	Cristiana Sessa Bellinzona, Switzerland
19:35	Proactive and reactive strategies for improving patient compliance and safety of VEGFR-TKI/immune checkpoint inhibitor combinations	Giuseppe Procopio Milan, Italy
19:50	Live conclusions	Tim Meyer London, UK
19:55	Q&A and live discussion	All

This educational activity is provided by ESMO and supported by Eisai Europe Ltd.

